Skip to main content
. 2020 Oct 29;34(6):2197–2210. doi: 10.1111/jvim.15925

TABLE 3.

Body weight, body condition score, and laboratory measurements in cats with subclinical hypertrophic cardiomyopathy randomized to Test or Control diet for 12 months

Test group (n = 23) Control group (n = 21)
Baseline 6 months 12 months Baseline 6 months 12 months
BW (kg) 5.0 (2.9‐8.7) 4.9 (2.7‐7.9) 4.9 (2.7‐7.7) 4.8 (3.2‐7.5) 4.9 (3.28‐7.8) 4.9 (3.2‐7.4)
Effect size (95% CI) 0.09 (−0.33; 0.51) 0.28 (−0.14; 0.71) 0.11 (−0.33; 0.55) 0.21 (−0.23; 0.66)
BCS (1‐9) 5 (3‐9) 6 (2‐8) 6 (2‐7) 5 (4‐7) 5 (3‐8) 5 (3‐7)
Effect size (95% CI) −0.06 (−0.48; 0.36) 0.15 (−0.27; 0.57) 0.06 (−0.38; 0.5) 0.15 (−0.29; 0.59)
Insulin (μU/mL) 24 (8.9‐113) 32.5 (6.6‐58) 42 (6.3‐70) 16.7 (3.9‐76) 24.2 (7.4‐123) 16.8 (6.2‐129)
Effect size (95% CI) −0.33 (−0.76; 0.1) −0.49 (−0.94; −0.05) −0.36 (−0.82; 0.09) −0.18 (−0.63; 0.26)
IGF‐1 (ng/mL) 460 (216‐772) 369 (118‐658) 401 (73.3720) a 448 (207‐786) 463 (66.5‐956) 498 (132‐1000)
Effect size (95% CI) 0.88 (0.4; 1.38) 0.61 (0.16; 1.07) −0.05 (−0.49; 0.39) −0.1 (−0.54; 0.33)
SAA (mg/L) 0 (0‐1.5) 0 (0‐34.5) 0 (0‐1.3) 0.0 (0.0‐21.8) 0.05 (0‐12.4) 0 (0‐34)
Odds ratio (95% CI) 1.00 (0.26; 3.81) 0.43 (0.08; 1.87) 2.20 (0.64; 7.96) 1.23 (0.35; 4.46)
NT‐proBNP (pmol/L) 211 (24‐1500) 98 (24‐1500) 150 (26‐1500) 271 (26‐1500) 199.5 (24‐1500) 263 (24‐1500)
Effect size (95% CI) 0.14 (−0.28; 0.56) −0.11 (−0.53; 0.31) −0.09 (−0.53; 0.35) −0.39 (−0.85; 0.06)
cTnI (ng/mL) 0.16 (0.02‐9.49) 0.07 (0.01‐0.55) b 0.12 (0.01‐.56) 0.14 (0.01‐1.74) 0.1 (0.01‐2.25) 0.1 (0.01‐2.35)
Effect size (95% CI) 0.37 (−0.06; 0.8) 0.33 (−0.1; 0.76) 0.02 (−0.41; 0.46) −0.23 (−0.68; 0.21)

Note: Data are presented as median and range (minimum‐maximum). There was no significant difference between diet groups at baseline. Text in bold indicates statistically significant differences for other timepoints compared with baseline.

Abbreviations: CI, confidence interval; BCS, body condition score; BW, bodyweight; cTNI, cardic troponin I; IGF‐1, insulin‐like growth factor‐1; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide; SAA, serum amyloid A.

a

P = .04 and

b

P = .001 for the comparisons with baseline of the Test group. Effect sizes (Cohen's d) between baseline and the stated timepoint are given for each variable within each diet group; SAA was analyzed as discrete (nominal) data and therefore odds ratios are shown instead.